Posted by Michael Wonder on 24 Feb 2021
ViiV Healthcare submits supplemental new drug application to US FDA for expanded use of Cabenuva (cabotegravir, rilpivirine) as an HIV treatment for use every 2 months
24 February 2021 - ViiV Healthcare announced today the submission of a supplemental new drug application to the US FDA for the expanded use of Cabenuva (cabotegravir, rilpivirine).
The supplemental new drug application seeks to expand Cabenuva’s label to include every 2 month dosing for the treatment of HIV-1 infection in virologically suppressed adults (HIV-1 RNA less than 50 copies/mL) on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine.
